Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
NCT05100095Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2021
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Merkel cell carcinoma (MCC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Local control rate at 2 years and Nodal control rate at 2 years. Started Dec 2021; status: recruiting.
02
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT05100095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100095.